Analyzing Generex Biotechnology (OTCMKTS:GNBT) & Skye Bioscience (NASDAQ:SKYE)

Generex Biotechnology (OTCMKTS:GNBT) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Valuation and Earnings

This table compares Generex Biotechnology and Skye Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generex Biotechnology	$2.66 million	0.00	-$33.33 million	N/A	N/A
Skye Bioscience	N/A	N/A	-$37.65 million	N/A	N/A

Generex Biotechnology has higher revenue and earnings than Skye Bioscience.

Insider and Institutional Ownership

21.1% of Skye Bioscience shares are held by institutional investors. 35.2% of Generex Biotechnology shares are held by insiders. Comparatively, 3.0% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Generex Biotechnology and Skye Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generex Biotechnology	N/A	N/A	N/A
Skye Bioscience	N/A	-45.78%	-37.44%

Analyst Recommendations

This is a summary of recent recommendations for Generex Biotechnology and Skye Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generex Biotechnology	0	0	0	0	0.00
Skye Bioscience	0	0	7	0	3.00

Skye Bioscience has a consensus price target of $18.67, indicating a potential upside of 609.76%. Given Skye Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Generex Biotechnology.

Volatility and Risk

Generex Biotechnology has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

About Generex Biotechnology

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

About Skye Bioscience

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.